SLC39A8 Antibody

What is SLC39A8/ZIP8 and why is it significant in research?

SLC39A8 (ZIP8) is a plasma membrane protein that mediates the specific uptake of several metal ions including Cd²⁺, Mn²⁺, Zn²⁺, Fe²⁺, Co²⁺, and Se⁴⁺ . This transporter has gained significant research attention due to its critical roles in:

• Metal ion homeostasis essential for cellular biochemical processes

• Regulation of inflammatory responses through zinc-mediated pathways

• Neurodevelopment and cerebellar functions

• Links to multiple diseases including congenital disorders of glycosylation (CDG type II), Leigh-like syndrome, inflammatory bowel disease, and schizophrenia

The protein localizes primarily to the plasma membrane but can also be found in lysosomal or mitochondrial membranes . It undergoes heavy glycosylation following stimulation, leading to increased expression of a high molecular weight, membrane-associated form .

What types of SLC39A8 antibodies are commonly used in research?

Researchers have several options when selecting SLC39A8 antibodies:

• Host species: Primarily rabbit-derived antibodies are available

• Clonality:

  • Polyclonal antibodies that recognize multiple epitopes of SLC39A8

  • Monoclonal antibodies (e.g., E2L8E) offering higher specificity and reproducibility

• Target regions:

  • Antibodies targeting extracellular domains

  • Antibodies targeting N-terminal regions

  • Antibodies targeting C-terminal regions

• Reactivity: Many commercially available antibodies react with human and rat SLC39A8, with some also recognizing mouse orthologs

What are the validated applications for SLC39A8 antibodies?

SLC39A8 antibodies have been validated for multiple applications, each with specific considerations:

How should I validate the specificity of an SLC39A8 antibody before use?

Proper validation is critical for reliable results. The following approaches are recommended:

• Pre-adsorption testing: Use a blocking peptide (the original immunization antigen) to confirm antibody specificity. For example, observed bands in Western blot should disappear when the antibody is pre-incubated with the blocking peptide .

• Positive controls: Include tissues or cells known to express high levels of SLC39A8, such as:

  • Kidney tissue (mouse, rat, or human)

  • Immune cells (particularly after stimulation with TNFα or LPS)

  • Cell lines with doxycycline-inducible SLC39A8 expression

• Negative controls:

  • Tissues from SLC39A8 knockout models

  • Cells treated with SLC39A8-specific siRNA

  • Primary antibody omission

• Cross-reactivity assessment: Verify that the antibody does not cross-react with other ZIP family members, which have structural similarities .

What considerations are important when using SLC39A8 antibodies for Western blotting?

For optimal Western blot results with SLC39A8 antibodies:

• Sample preparation:

  • For membrane proteins like SLC39A8, use a lysis buffer containing non-ionic detergents (e.g., 1% NP-40)

  • Include protease inhibitors to prevent degradation

  • For inducible systems, confirm expression with doxycycline induction (1 μg/ml for 24 hours)

• Expected molecular weights:

  • Monomeric form: ~65-75 kDa

  • Dimeric form: ~130-200 kDa

  • Note that glycosylation may increase observed molecular weights

• Controls and normalization:

  • Include GAPDH as a loading control

  • For variant studies, compare to wild-type SLC39A8 run on the same gel

• Dilution ratios:

  • Most commercial antibodies perform optimally at 1:200 to 1:1000 dilution

What protocol considerations apply when using SLC39A8 antibodies for immunofluorescence studies?

When designing immunofluorescence experiments with SLC39A8 antibodies:

• Fixation method:

  • For plasma membrane localization: 4% formaldehyde in PBS for 10 minutes at room temperature

  • For ER co-localization studies: ice-cold methanol for 10 minutes at -20°C followed by PBS rehydration

• Co-localization markers:

  • Plasma membrane: Cell mask or other membrane markers

  • ER: Anti-calreticulin antibody

  • Other organelles: Appropriate markers based on experimental question

• Blocking and antibody incubation:

  • Block with 0.5% BSA and 0.15% glycine in PBS for 1 hour at room temperature

  • Primary antibody incubation overnight at 4°C

  • Secondary antibody selection based on host species (typically anti-rabbit)

• Quantification approaches:

  • Pearson correlation coefficient can be calculated between SLC39A8 signals and organelle markers to quantify subcellular localization

  • At least 4 replicates should be analyzed for statistical validity

How can I investigate the effects of SLC39A8 variants on protein localization and function?

The study of SLC39A8 variants requires a methodical approach:

• Expression system setup:

  • Generate stable cell lines expressing wild-type or variant SLC39A8, ideally with inducible expression systems

  • Tag constructs with epitope tags (e.g., HA, STREPII) for detection if antibodies against specific variants are unavailable

• Localization analysis:

  • Perform immunofluorescence co-localization with organelle markers

  • Quantify correlation coefficients between SLC39A8 signal and markers for:

    • Plasma membrane (proper localization)

    • Endoplasmic reticulum (potential retention/misfolding)

    • Other relevant compartments

• Functional assessment:

  • Metal uptake assays to measure transport of Cd²⁺, Mn²⁺, and Zn²⁺

  • ICP-MS analysis to quantify intracellular metal concentrations

  • Competition assays between different metal ions

• Expression level verification:

  • Western blot analysis to confirm expression of the variant protein

  • Assessment of both monomeric (~75 kDa) and dimeric (~200 kDa) forms

Research using this approach has classified SLC39A8 variants into distinct functional categories:

• Variants with disrupted expression

• Variants with high ER retention

• Variants with normal plasma membrane localization but impaired transport

• Variants with selective metal transport deficiencies

How can SLC39A8 antibodies be used to study inflammatory responses?

SLC39A8 plays an important role in inflammatory regulation through its relationship with NF-κB signaling:

• Stimulation experiments:

  • Treat cells with inflammatory stimuli (TNFα, LPS) to induce SLC39A8 expression

  • Use time-course studies with antibody detection to track expression changes

• Pathway analysis:

  • Combine SLC39A8 antibodies with antibodies against NF-κB pathway components

  • Use ChIP assays with anti-NF-κB p65 to examine binding to the SLC39A8 promoter region

• Feedback regulation studies:

  • Manipulate SLC39A8 expression using genetic approaches

  • Measure NF-κB activity using reporter assays

  • Use antibodies to detect changes in inflammatory pathway components

• Metal supplementation studies:

  • Combine antibody detection of SLC39A8 with zinc supplementation/depletion

  • Monitor effects on inflammatory markers

What approaches can be used to study SLC39A8's role in neurological disorders?

Given SLC39A8's implications in schizophrenia and neurodevelopmental disorders , several specialized approaches are valuable:

• Brain region-specific analysis:

  • Immunohistochemistry to map SLC39A8 expression in different brain regions

  • Focus on regions implicated in schizophrenia and development (cerebellum, hippocampus)

• Animal models:

  • SLC39A8 knockout or knockin (e.g., A391T) mouse models

  • Use antibodies to confirm altered expression patterns

  • Correlate with behavioral and developmental phenotypes

• Manganese homeostasis:

  • Combine antibody detection with manganese quantification in brain tissue

  • Assess impact of genetic variants on manganese uptake

  • Study glycosylation patterns affected by manganese availability

• Human sample studies:

  • Compare SLC39A8 expression in post-mortem brain samples from individuals with schizophrenia versus controls

  • Stratify by genetic status at rs13107325 (A391T) locus

Why might I observe different molecular weights for SLC39A8 in Western blots, and how should I interpret them?

Variability in SLC39A8's apparent molecular weight is common and can provide valuable information:

• Expected weight patterns:

  • Theoretical molecular weight: ~49.6 kDa based on amino acid sequence

  • Observed monomeric form: ~65-75 kDa due to glycosylation

  • Dimeric form: ~130-200 kDa

• Causes of variation:

  • Post-translational modifications: SLC39A8 is heavily glycosylated following stimulation, increasing its molecular weight

  • Dimerization: SLC39A8 can form homodimers resistant to denaturation in some sample preparation conditions

  • Tissue differences: Expression patterns and post-translational modifications may vary between tissues

  • Stimulation status: LPS or TNFα stimulation increases glycosylation

• Interpretation strategies:

  • Compare observed patterns with positive controls

  • Use glycosylation inhibitors or deglycosylation enzymes to confirm glycosylation contributions

  • Include reducing agents in sample buffer to assess disulfide bond contributions to dimerization

How do I address and interpret contradictory localization data for SLC39A8?

Conflicting localization data may reflect biological complexity rather than experimental error:

• Known localizations:

  • Primary localization: Plasma membrane

  • Secondary localizations: Lysosomal membranes, mitochondrial membranes

  • ER localization may indicate immature/misfolded protein or variants with trafficking defects

• Factors affecting localization:

  • Cell type: Different cells may show different predominant localizations

  • Stimulation status: Inflammatory stimuli may alter trafficking

  • Genetic variants: Many variants show altered localization patterns

  • Expression level: Overexpression systems may saturate trafficking machinery

• Resolution approaches:

  • Use multiple antibodies targeting different epitopes

  • Perform cell fractionation followed by Western blotting

  • Employ super-resolution microscopy for detailed localization

  • Use epitope-tagged constructs as an alternative approach

What controls are essential when comparing SLC39A8 antibody results across different experimental conditions?

Rigorous controls are crucial for valid comparisons:

• Expression level controls:

  • Use housekeeping proteins (GAPDH, β-actin) for Western blot normalization

  • Quantify total protein loading using stain-free gels or Ponceau staining

• Specificity controls:

  • Blocking peptide pre-adsorption to confirm specific binding

  • SLC39A8 knockdown/knockout samples as negative controls

  • Isotype control antibodies to assess non-specific binding

• Cross-experiment standardization:

  • Include a common reference sample across blots/experiments

  • Use the same antibody lot when possible

  • Standardize image acquisition settings

• Functional controls for variant studies:

  • Include wild-type SLC39A8 in all experiments

  • Use known functional variants (e.g., A391T) as reference points

  • Validate expression levels before interpreting functional differences

How are SLC39A8 antibodies being used to study intestinal barrier function and inflammatory bowel disease?

Recent research has revealed SLC39A8's role in intestinal barrier integrity:

• Experimental approaches:

  • Immunohistochemistry to examine SLC39A8 expression in intestinal epithelia

  • Combine with glycocalyx staining to assess barrier integrity

  • Use SLC39A8 A391T knockin mice as models for Crohn's disease susceptibility

• Key findings:

  • SLC39A8 A391T variant causes severe manganese deficiency in the colon

  • This leads to impaired intestinal barrier integrity due to glycoprotein barrier structure defects

  • The resulting bacterial invasion promotes inflammation, particularly after epithelial injury

• Research applications:

  • Study SLC39A8 expression in IBD patient samples

  • Test manganese supplementation effects on barrier function

  • Investigate interactions between SLC39A8 function and the gut microbiome

What techniques combine SLC39A8 antibodies with metal analysis to study transporter function?

Advanced multi-technique approaches provide comprehensive insights:

• Combined methodologies:

  • Immunofluorescence for localization + ICP-MS for metal quantification

  • Western blotting for expression levels + metal uptake assays

  • Co-immunoprecipitation + metal analysis to study metal binding

• Metal competition studies:

  • Use antibodies to confirm equal SLC39A8 expression

  • Perform uptake assays with different metal combinations

  • Identify metal preferences and variant-specific transport patterns

• Structural-functional correlations:

  • Combine antibody detection with in silico analysis of protein stability

  • Link variant localization patterns with predicted effects on dimer interfaces

  • Correlate observed metal transport with structural predictions

How can researchers investigate links between SLC39A8 function and neurodevelopmental disorders?

The association between SLC39A8 variants and neurological conditions opens important research directions:

• Brain development studies:

  • Use antibodies to track SLC39A8 expression during cerebellar development

  • Focus on neuron-specific SLC39A8 knockout models (Slc39a8-NSKO)

  • Correlate manganese deficiency with developmental abnormalities

• Glycosylation investigation:

  • Examine N-glycome profiles in relation to SLC39A8 function

  • Compare profiles between wild-type and variant carriers

  • Test reversibility through manganese supplementation

• Cognitive correlation studies:

  • Analyze SLC39A8 variants in relation to cognitive performance metrics

  • Study rs13107325 (A391T) carriers for cognitive phenotypes

  • Investigate potential mechanistic links through manganese-dependent processes

• Therapeutic exploration:

  • Use antibodies to confirm SLC39A8 expression before and after interventions

  • Test manganese supplementation as a potential therapeutic approach

  • Investigate compounds that might enhance residual SLC39A8 function in variant carriers